Cochrane · systematic review · CD007583
Radiotherapy and chemoradiation after surgery for early cervical cancer
Rogers, L, Siu, SSN, Luesley, D, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySummary of findings: comparison of radiotherapy with no further treatment
Population: patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death within 5 years | RR 0.84 [0.3, 2.36] | 2 studies · 397 participants | Moderate Downgraded: imprecision, inconsistency |
Disease progression within 5 years | RR 0.58 [0.37, 0.91] | 2 studies · 397 participants | Moderate Downgraded: imprecision, inconsistency |
Haematological adverse events (grade 3 or 4) | RR 2.38 [0.63, 9.05] | 2 studies · 388 participants | Moderate Downgraded: imprecision, inconsistency |
Gastrointestinal adverse events (grade 3 or 4) | RR 7.32 [0.91, 58.82] | 2 studies · 388 participants | Moderate Downgraded: imprecision, inconsistency |
Genitourinary adverse events (grade 3 or 4) | RR 2.12 [0.54, 8.37] | 2 studies · 388 participants | Moderate Downgraded: imprecision, inconsistency |
Summary of findings: comparison of radiotherapy with no further treatment
Population: patients with early stage cervical cancer (FIGO stages IB1, IB2 or IIA)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death within 5 years | RR 0.84 [0.3, 2.36] | 2 studies · 397 participants | Moderate Downgraded: imprecision, inconsistency |
Disease progression within 5 years | RR 0.58 [0.37, 0.91] | 2 studies · 397 participants | Moderate Downgraded: imprecision, inconsistency |
Haematological adverse events (grade 3‐4) | RR 2.38 [0.63, 9.05] | 2 studies · 388 participants | Moderate Downgraded: imprecision, inconsistency |
Gastrointestinal adverse events (grade 3‐4) | RR 7.32 [0.91, 58.82] | 2 studies · 388 participants | Moderate Downgraded: imprecision, inconsistency |
Genitourinary adverse events (grade 3‐4) | RR 2.12 [0.54, 8.37] | 2 studies · 388 participants | Moderate Downgraded: imprecision, inconsistency |